TrialBlood advances2026
Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up.
Roger G Owen et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
2 papers cite it
this papercites it
TrialBlood advances2026
Roger G Owen et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.